

<b>Reference:</b>	FOI.16052.24
<b>Subject:</b>	Treatment of inflammatory diseases
<b>Date of Request:</b>	25 November 2024

**Your request and our response**

1. How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jul 2024 to the end of Sept 2024?  
Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.

Hywel Dda University Health Board (UHB) provides the number of Dermatology, Gastroenterology and Rheumatology patients who were treated with the listed medications, for any disease, during the period 1 July to 30 September 2024, in the table overleaf.

Where the figures in the table have been replaced with an asterisk (\*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Gastroenterology</b>	<b>Rheumatology</b>
Adalimumab	73	154	286
Apremilast	8	0	31
Bimekizumab	*	0	*
Brodalumab	*	0	0
Certolizumab Pegol	*	0	45
Deucravacitinib	0	0	0
Etanercept	*	0	200
Guselkumab	*	0	0
Infliximab (Remicade)	0	*	0
Infliximab (Biosimilars)	*	92	16
Ixekizumab	*	0	11
Risankizumab	22	19	0
Secukinumab	35	0	49
Tildrakizumab	*	0	0
Ustekinumab	22	118	11
Upadacitinib	0	34	19
Vedolizumab	0	106	*
Filgotinib	0	9	*

Golimumab	0	0	31
Mirikizumab	0	0	0
Ozanimod	0	*	0
Etrasimod	0	0	0
Tofacitinib	0	*	5
Baricitinib	0	0	61
Rituximab	0	*	19
Sarilumab	0	0	9
Tocilizumab	0	0	88
<b>Total</b>	<b>171</b>	<b>540</b>	<b>889</b>

2. How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of Jul 2024 to the end of Sept 2024? *Please use the latest available 3 months if Jul to Sept is not available and specify which 3 months has been used.*

The UHB has provided the number of Dermatology, Gastroenterology and Rheumatology patients who were treated with Ustekinumab and its biosimilars, for any disease, during the period 1 July to 30 September 2024, in the table below.

<b>Drug Name</b>	<b>Dermatology</b>	<b>Gastroenterology</b>	<b>Rheumatology</b>
Ustekinumab (Stelara)	22	118	11
Ustekinumab (Pyzchiva)	0	0	0
Ustekinumab (Uzpruvo)	0	0	0
Ustekinumab (Wezenla)	0	0	0
<b>Total</b>	<b>22</b>	<b>118</b>	<b>11</b>